Clinical Trial

Sensitech Completes Acquisition of Berlinger & Co. Monitoring Solutions Expanding Life Sciences Cold Chain Solutions

BEVERLY, Mass., Aug. 2, 2024 /PRNewswire/ -- Carrier Global Corporation, on behalf of its Sensitech business, a world leader in…

2 years ago

Chronic Prostatitis or Pelvic Pain Syndrome Treatment with Dr Allen’s Device Safely Prevents Prostate Enlargement (BPH)

Thermobalancing therapy with Dr Allen's Device treats chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) effectively and safely, helping to…

2 years ago

Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01

Calgary, Alberta--(Newsfile Corp. - August 1, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to…

2 years ago

Distinguished experts join Verantos inflammatory bowel disease advisory panel

High-validity RWE company welcomes Cheifetz and Melmed PALO ALTO, Calif., Aug. 1, 2024 /PRNewswire/ -- Verantos, the global leader in high-validity…

2 years ago

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ETDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company…

2 years ago

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of…

2 years ago

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of…

2 years ago

Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of…

2 years ago

Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of…

2 years ago

Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates

Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial…

2 years ago